According to the World Health Organization, cardiovascular disease is the leading cause of death in the United States and worldwide. In fact, about 17.9 million people die from cardiovascular disease each year, accounting for an estimated 31 percent of deaths worldwide. Yet despite cardiovascular disease being a continual, significant threat to human health, investment in cardiovascular drug development has stagnated in the past two decades. Even as investment and innovation in therapeutic areas have soared, cardiovascular drug development is precipitously declining. With its new partnership with a trusted collaborator, QPS hopes to aid in the development of cardiovascular drugs.
For over three years, QPS has collaborated with G-CURE, a cardiovascular research organization originating from and closely linked to the Department of Cardiology at the University Medical Center Groningen (UMCG) in the Netherlands. Now, QPS and G-CURE are partnering to form a globally competitive cardiovascular drug development infrastructure that will provide drug development programs for pharmaceutical and biotech companies. With their vast experience and expertise in cardiovascular research, Phase I clinical pharmacology, and Phase II-IV cardiovascular clinical trials, QPS and G-CURE hope to make great strides in the development of cardiovascular drugs.
Within this new partnership, G-CURE will take charge of preclinical, experimental, and translational (animal) studies as well as the patient phases of projects. QPS will conduct the healthy volunteer phases of new projects, closely collaborating with UMCG and G-CURE, and may provide bioanalysis and clinical research support for Phase I-IV clinical trials using their local laboratories and offices.
With their adept understanding of cardiovascular physiology and pathophysiology, the team of cardiovascular specialists involved in the partnership can provide exceptional value to clients. They will focus on several specific target areas:
- Amyloidosis
- Genetic Cardiomyopathies
- Acute Coronary Syndromes
- Arrhythmias (in particular Atrial Fibrillation)
- Heart Failure
_____
Due to improvements in lifestyle and effective treatments, the age-adjusted death rates for cardiovascular disease in the United States decreased by 60 percent from 1950 to 1999 (source). Unfortunately, cardiovascular disease mortality rates are no longer in decline; for some populations, they’re actually increasing.
The demand for new therapies for cardiovascular disease is high, and QPS and G-CURE are poised to help with their new partnership. If you are interested in learning more about QPS and G-CURE’s drug development capabilities or you would like to work with them in this exciting new partnership, please reach out to one of the following contacts:
QPS Holdings, LLC:
Edwin Van Vulpen, Head of Clinical Business Development Europe
+31 61 0000195
UMCG/G-CURE:
Ruben de Jong, COO G-CURE & Head Cardio Research
+31 50 3613875
Since 1995, QPS has provided discovery, preclinical, and clinical drug development services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. For more information, visit www.qps.com or email [email protected].
